Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.45 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.43 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.42 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 2/20 | 0.41 |
| ▸ | LIPE | Q05469 | 4/20 | 0.39 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10113339 | 0.91 | ALDH1A1 (0.46) | USP30UCHL1GPR119LIPGSCN3A | |
| SCHEMBL648582 | 0.89 | UCHL1 (0.43) | USP30UCHL1GPR119LIPGSCN3A | |
| SCHEMBL3665469 | 0.89 | LIPG (0.45) | USP30UCHL1GPR119LIPGLIPE | |
| SCHEMBL648845 | 0.88 | LIPE (0.45) | USP30UCHL1GPR119HTR7LIPE | |
| SCHEMBL649734 | 0.87 | GPR119 (0.58) | GPR119 | |
| SCHEMBL4401672 | 0.86 | LIPE (0.44) | USP30UCHL1GPR119LIPEPRKAA2 | |
| SCHEMBL650729 | 0.86 | LIPE (0.43) | USP30UCHL1HTR7LIPEPRKAA2 | |
| SCHEMBL12225951 | 0.85 | PRKAA2 (0.46) | USP30UCHL1HTR7LIPEPRKAA2 | |
| SCHEMBL649826 | 0.84 | PRKAA2 (0.52) | LIPEPRKAA2 | |
| SCHEMBL648221 | 0.84 | HTR1A (0.46) | HTR7LIPEHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115838-A1 | AMPK-Activating Heterocycloalkyloxy(Hetero)Aryl Carboxamide, Sulfonamide And Amine Compounds And Methods For Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115838-A1 | AMPK-Activating Heterocycloalkyloxy(Hetero)Aryl Carboxamide, Sulfonamide And Amine Compounds And Methods For Using The Same | PRKAA1, PRKAA2, PRKAG1 | USP30 2371/4885UCHL1 2457/4885GPR119 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.